Health
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT® (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Cana
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various conditions including endometriosis, uterine fibroids, and central precocious puberty.1","length":280,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":280,"olType":false},{"type":"text","content":"MONTREAL, Nov. 17, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT® (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Canada.","length":535,"tagName":"p"},{"type":"image","alt":"AbbVie Canada (CNW Group/AbbVie Canada)","displaySize":"","headline":null,"caption":"AbbVie Canada (CNW Group/AbbVie Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":70,"url":"https://media.zenfs.com/en/cnwgroup.com/915f008039b56738ddadc58747abee7f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CDqCQyx8pScp4xdHkEw_Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/915f008039b56738ddadc58747abee7f","width":400,"height":70}},"href":"https://mma.prnewswire.com/media/2823662/AbbVie_Canada_LUPRON_DEPOT__new_strength_receives_Health_Canada.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Advanced prostate cancer can have a devastating impact on patients and their quality of life," says Dr. Andrew Loblaw, Clinician Scientist and Head of Genitourinary Radiation Oncology Clinical Studies Group. "As a physician, I am pleased to know that my patients will be able to access a treatment that helps reduce the administration burden many often experience. This announcement marks a significant advancement in how we treat and manage advanced prostate cancer for years to come."","length":507,"tagName":"p"},{"type":"text","content":"Prostate cancer is the most prevalent cancer among Canadian men, representing on...